Genomics
Sequencing platforms, gene editing, therapeutic discovery. The point at which biology becomes engineering.
Twenty-six years of selective capital deployment in the technologies that will shape the next century.
View the DomainsTera AG was founded in 2000 and operates from Beijing. The capital is privately held. Decisions are taken on a horizon measured in decades, not quarters.
The portfolio is concentrated in industries with structural rather than cyclical demand. Hard engineering, contested regulatory ground, long time-to-scale. The kind of work that rewards patience and punishes the alternative.
Discretion is part of the operating model. Portfolio companies are not named publicly. The work is done in the open with the people who matter, and quietly with everyone else.
Six fields. Each chosen on the same test: does the asset compound across cycles, or does it depend on a moment passing.
Sequencing platforms, gene editing, therapeutic discovery. The point at which biology becomes engineering.
Civil and defence airframes, propulsion, autonomous flight. Capital-intensive, regulated, durable.
Deep-well baseload power. The most underwritten resource on the planet.
Factory-built reactors. The realistic decarbonisation pathway, eventually conceded.
Foundation models, applied systems, the silicon they run on.
Allocations to fields that will be obvious in ten years and dismissed today.
From near zero in 2000 to fifteen billion in 2026. The chart is the actual curve, not a projection.
Four principles. None of them invented for the website.
We hold positions for decades. Not as virtue. As arithmetic. The assets we want take that long to compound.
We say no most of the time. Concentration is the point.
Capital is necessary and not sufficient. Operators inside the portfolio do the actual work.
Public attention is not a deliverable. Performance is.
For institutional and qualified counterparts.